EBOS Group Limited (EBO:AX, EBO.NZ)John Cullity CEO ElectASX CEO Connect Series – March 2018

2

ANIMAL CAREHEALTHCARE

EBOS Group Today

COMMUNITY PHARMACY

CONSUMER PRODUCTS

INSTITUTIONAL HEALTHCARE

CONTRACT LOGISTICS RETAIL

PRODUCT & BRANDS

VET WHOLESALE

NZ$2.7BMarket Capitalisation

NZX/ASX Dual listed

$7.6 billionFY17 Revenue

21%Annualised shareholder return last 4 Years

No.1Combined pharmacy and hospital pharmaceutical wholesaler in Australia & NZ

Investments

3

EBOS Group strategic approach

Investing for Growth Leading Market Positions

Disciplined Capital Management

• Cash generation to drive scope for further investment which allows for dividends paid in the range of 60-70% of Net Profit After Tax

• Acquisitions focus on improving Group returns on capital employed

Our Healthcare and Animal Care strategic focus is centred on:

We aim to have positions of scale in the markets we operate in and maximise opportunities across our wide range of business segments wherever possible

Two types of investments:

• External acquisitions – we have a strong history of deal execution

• Internal Capex – investment to lift productivity, manage cost and deliver better customer service

We focus on delivering profitable growth and superior returns

4

Recent Investment HighlightsRecent Acquisitions & Investments Major Capacity Expansion

TWC Investment: October 2016• Merger of Chemmart and Terry

White has created of one of the largest retail pharmacy store networks in Australia.

HPS Acquired: June 2017• Australia’s largest provider of

outsourced pharmacy services to Hospitals.

Significant progress made on three key capex projects in Australia & NZ• New Wholesale Distribution site

Brisbane, Queensland

• New Contract Logistics siteSydney, New South Wales

• New Wholesale Distribution siteChristchurch, NZ

BlackHawk expansion: July 2017• BH launched into the New Zealand

market• BH is now Australia’s and NZ’s fastest

growing premium pet food.

MedAdvisor investment: October 2017 • Cornerstone investment made in

Australia’s leading digital medication management company Construction progress: New Brisbane site (Queensland)

5

• Australia’s fastest growing premium pet food brand with a leading position in the pet specialty retail channel.

• Sales growth in 1H 2018 of +26%

• In July 2017 Black Hawk was launched in the New Zealand market. Initial results are very positive.

Black Hawk Update

FY14 FY15 FY16 FY17

Black Hawk Sales (pre and post acquisition)

+48%

+55%

+23%

6

Constant FXNZ$m H1 FY18 H1 FY17 Var VarRevenue 3,942.7 3,960.2 (0.4%) (3.8%)

Gross Operating Revenue 434.8 364.1 19.4% 15.5%

EBITDA 138.5 119.9 15.6% 11.7%

EBIT 121.2 107.5 12.7% 9.0%

Net Profit After Tax 76.7 68.8 11.5% 7.8%

Underlying EBITDA 138.5 122.3 13.3% 9.5%

Underlying NPAT 76.7 70.2 9.1% 5.5%

Adjusted EPS - cps 51.4 46.4 10.8% 7.1%

Net Debt 447.5 288.1

Net Debt : EBITDA 1.76x 1.25x

ROCE 16.1% 16.2%

EBOS 1H FY18 Summary results

7

Delivering Results

1,822

5,757

6,395

7,101

7,626

FY13

FY14

FY15

FY16

FY17

57.0

175.4

215.7

225.5

241.4

FY13

FY14

FY15

FY16

FY17

41.0 47.0 58.5 63.0

FY14 FY15 FY16 FY17

5 Year Revenue TrendNZ$m

Dividends per sharecents

5 Year EBITDA TrendNZ$m

6

8

10

12

14

16

18

20

30/06/2012 30/06/2013 30/06/2014 30/06/2015 30/06/2016 30/06/2017

Share PriceFY13 to FY17

8

Summary - what to expect

• Continue to execute on our strategy of organic growth and bolt on acquisitions

• Maintain our disciplined approach to cash flow and capital management

• Maintain a strong balance sheet with capacity for acquisition opportunities

• Focus on our customers, partners and shareholder returns

www.ebosgroup.com